Loading...
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie, P Marshall, A Nathan, P Gore, M Tahir, S Faust, G Kelly, C Marples, M Danson, S
Corrie, P
Marshall, A
Nathan, P
Gore, M
Tahir, S
Faust, G
Kelly, C
Marples, M
Danson, S
Citations
Altmetric:
Abstract
Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence.
Authors
Corrie, P
Marshall, A
Nathan, P
Lorigan, Paul C
Gore, M
Tahir, S
Faust, G
Kelly, C
Marples, M
Danson, S
Marshall, E
Houston, S
Board, R
Waterston, A
Nobes, J
Harries, M
Kumar, S
Goodman, A
Dalgleish, A
Martin-Clavijo, A
Westwell, S
Casasola, R
Chao, D
Maraveyas, A
Patel, P
Ottensmeier, C
Farrugia, D
Humphreys, A
Eccles, B
Young, G
Barker, E
Harman, C
Weiss, M
Myers, K
Chhabra, A
Rodwell, S
Dunn, J
Middleton, M
Marshall, A
Nathan, P
Lorigan, Paul C
Gore, M
Tahir, S
Faust, G
Kelly, C
Marples, M
Danson, S
Marshall, E
Houston, S
Board, R
Waterston, A
Nobes, J
Harries, M
Kumar, S
Goodman, A
Dalgleish, A
Martin-Clavijo, A
Westwell, S
Casasola, R
Chao, D
Maraveyas, A
Patel, P
Ottensmeier, C
Farrugia, D
Humphreys, A
Eccles, B
Young, G
Barker, E
Harman, C
Weiss, M
Myers, K
Chhabra, A
Rodwell, S
Dunn, J
Middleton, M
Description
Date
2018-08-01
Publisher
Collections
Files
Keywords
Type
Article
Citation
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. 2018, 29(8): 1843-1852 Ann Oncol